Gland Pharma receives EIR from US FDA for Dundigal facility after successful GMP inspection

Gland Pharma has received an Establishment Inspection Report (EIR) from the US FDA, confirming the successful closure of the Good Manufacturing Practices (GMP) inspection at its Dundigal facility in Hyderabad.

The inspection took place from July 22nd to July 25th, 2024. This marks a significant milestone for the company, ensuring compliance with international quality standards. Gland Pharma continues to uphold its commitment to maintaining the highest manufacturing standards and quality assurance processes.

Advertisement

Key Takeaways:

  • Gland Pharma’s Dundigal facility passed the US FDA GMP inspection.
  • The inspection was conducted between July 22nd and July 25th, 2024.
  • The company received the EIR, indicating the successful closure of the inspection.

In the meantime, Gland Pharma’s stock opened at ₹1,686.95, reaching a high of ₹1,719.00 and a low of ₹1,669.15 during the day. The stock is trading significantly lower than its 52-week high of ₹2,220.95, with the 52-week low recorded at ₹1,590.00.